H.C. Wainwright Believes Antares Pharma (NASDAQ: ATRS) Still Has Room to Grow

By Carrie Williams

In a report released today, Oren Livnat from H.C. Wainwright assigned a Buy rating to Antares Pharma (NASDAQ: ATRS), with a price target of $5. The company’s shares closed yesterday at $3.73, close to its 52-week high of $4.09.

According to TipRanks.com, Livnat is a 1-star analyst with an average return of -4.3% and a 40.0% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Pernix Therapeutics, and Horizon Pharma Inc.

Currently, the analyst consensus on Antares Pharma is Strong Buy and the average price target is $5, representing a 34.0% upside.

In a report issued on October 10, Jefferies also reiterated a Buy rating on the stock with a $6 price target.

Based on Antares Pharma’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $13.42 million and GAAP net loss of $2.84 million. In comparison, last year the company earned revenue of $13.48 million and had a GAAP net loss of $6.12 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Antares Pharma, Inc. is a pharmaceutical company. The company focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its activities include the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.